These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 35246479)

  • 1. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
    Maksymetz J; Moran SP; Conn PJ
    Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of mGlu
    Ghoshal A; Moran SP; Dickerson JW; Joffe ME; Grueter BA; Xiang Z; Lindsley CW; Rook JM; Conn PJ
    ACS Chem Neurosci; 2017 Oct; 8(10):2254-2265. PubMed ID: 28679049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
    Gregory KJ; Herman EJ; Ramsey AJ; Hammond AS; Byun NE; Stauffer SR; Manka JT; Jadhav S; Bridges TM; Weaver CD; Niswender CM; Steckler T; Drinkenburg WH; Ahnaou A; Lavreysen H; Macdonald GJ; Bartolomé JM; Mackie C; Hrupka BJ; Caron MG; Daigle TL; Lindsley CW; Conn PJ; Jones CK
    J Pharmacol Exp Ther; 2013 Nov; 347(2):438-57. PubMed ID: 23965381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
    Stansley BJ; Conn PJ
    Curr Opin Pharmacol; 2018 Feb; 38():31-36. PubMed ID: 29486374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K; Aoki T; Shimazaki Y
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.
    Walker AG; Conn PJ
    Curr Opin Pharmacol; 2015 Feb; 20():40-5. PubMed ID: 25462291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
    Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
    Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia.
    Nicoletti F; Orlando R; Di Menna L; Cannella M; Notartomaso S; Mascio G; Iacovelli L; Matrisciano F; Fazio F; Caraci F; Copani A; Battaglia G; Bruno V
    Front Psychiatry; 2019; 10():49. PubMed ID: 30890967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
    Noetzel MJ; Jones CK; Conn PJ
    Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
    Chavez-Noriega LE; Schaffhauser H; Campbell UC
    Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).
    Lindsley CW; Stauffer SR
    Pharm Pat Anal; 2013 Jan; 2(1):93-108. PubMed ID: 24236973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
    Rook JM; Xiang Z; Lv X; Ghoshal A; Dickerson JW; Bridges TM; Johnson KA; Foster DJ; Gregory KJ; Vinson PN; Thompson AD; Byun N; Collier RL; Bubser M; Nedelcovych MT; Gould RW; Stauffer SR; Daniels JS; Niswender CM; Lavreysen H; Mackie C; Conde-Ceide S; Alcazar J; Bartolomé-Nebreda JM; Macdonald GJ; Talpos JC; Steckler T; Jones CK; Lindsley CW; Conn PJ
    Neuron; 2015 May; 86(4):1029-1040. PubMed ID: 25937172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptors as therapeutic targets for schizophrenia.
    Vinson PN; Conn PJ
    Neuropharmacology; 2012 Mar; 62(3):1461-72. PubMed ID: 21620876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
    Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mGlu
    Maksymetz J; Byun NE; Luessen DJ; Li B; Barry RL; Gore JC; Niswender CM; Lindsley CW; Joffe ME; Conn PJ
    Cell Rep; 2021 Nov; 37(5):109950. PubMed ID: 34731619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S; Hikichi H
    Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
    Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia.
    Wierońska JM; Kłeczek N; Woźniak M; Gruca P; Łasoń-Tyburkiewicz M; Papp M; Brański P; Burnat G; Pilc A
    Neurochem Int; 2015 Sep; 88():97-109. PubMed ID: 25863284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.